Immutep CEO Marc Voigt joined @sharecafetweets Rachael Jones to discuss the company's next phase of clinical development, including its focus on head and neck cancer and soft tissue sarcoma, progress with IMP761, and key milestones planned for 2027. bit.ly/4dEMM7A

Immutep has an abstract accepted at #ESMO2026 in Madrid (23–27 Oct). The ePoster presents HRQoL data from the EFTISARC-NEO Phase II trial of efti + pembrolizumab + radiotherapy in soft tissue sarcoma. More details here: bit.ly/4pK7WGg #LAG3 #Immunotherapy #Oncology

Immutep is pleased to announce the grant of a fourth U.S. patent covering eftilagimod alfa (efti) in combination with anti-PD-1/PD-L1 therapies for cancer treatment. This patent strengthens our IP portfolio and supports future opportunities for efti. bit.ly/4w20loL

Immutep announces a positive update from the INSIGHT-003 Phase I trial, with mature data showing median overall survival of 30.9 months in 1L non-squamous NSCLC. The Company also provided a TACTI-004 update, with further analysis expected in Q3 CY2026. bit.ly/4voCqi4

Immutep Limited CEO and Executive Director, Marc Voigt, spoke with @sharecafetweets to discuss the Company's next steps following the discontinuation of the TACTI-004 trial. In the interview, Marc confirms the Company remains well funded with cash runway extending into the first half of 2028 and provides an update on the ongoing root cause analysis across clinical, analytical and manufacturing areas to determine the future pathway for eftilagimod alpha. Marc also highlights the continued advancement of Immutep's broader pipeline, including the IMP761 autoimmune program, with first Phase I data expected to be presented at the EULAR conference in London on 4 June and upcoming milestones including an ASCO poster presentation in Chicago and completion of the root cause analysis, guided for Q3. Watch the full interview here: bit.ly/4nBhl1N

@Immutep is pleased to announce that the U.S FDA has granted Orphan Drug Designation (ODD) for efti for the treatment of Soft Tissue Sarcoma (STS), a rare cancer with significant unmet medical need. This designation supports development in a rare cancer with significant unmet need and is backed by Phase II EFTISARC-NEO data showing encouraging tumour response and a favourable safety profile in combination with radiotherapy and KEYTRUDA. CEO of Immutep, Marc Voigt said: “We are pleased that the FDA has recognised the potential of efti for patients with soft tissue sarcoma, a rare and difficult to treat cancer. As previously communicated, the Company is currently undertaking a comprehensive review and analysis following the discontinuation of its Phase III TACTI-004 trial and the outcome will influence the decision regarding any potential future clinical trial with efti. The FDA’s designation, based on very encouraging data from the EFTISARC-NEO trial, provides us with a potential direct step forward into a late-stage study in the neoadjuvant setting for STS.” #biotech #oncology #clinicaltrials #raredisease #immunotherapy #FDA

@Immutep has provided an investor update following the recent discontinuation of the TACTI‑004 Phase III trial in first‑line non‑small cell lung cancer. A thorough root cause analysis is underway to understand factors contributing to the trial’s futility outcome. This work is essential not only for interpreting TACTI‑004, but also for guiding future development decisions across the broader efti pipeline. Immutep's portfolio continues to include multiple differentiated assets, including IMP761 with upcoming data in early June. Read the full update here: bit.ly/4tCNec7

Immutep CEO & Executive Director, Marc Voigt, appeared on FNN to discuss the Phase III TACTI-004 trial update following the interim futility analysis, and the decision to discontinue the study. In the interview Marc outlines the Company’s next steps, including a detailed review of the data and ongoing strategic planning, and highlights continued progress across Immutep’s broader clinical pipeline, with multiple programs advancing and further key milestones ahead. Link to the full video here: bit.ly/478fGtB

@Immutep announces today that the TACTI-004 trial in first line non-small cell lung cancer has enrolled 378 patients, representing 50% of the trial's target enrolment. Marc Voigt, CEO of Immutep, said, “The excellent pace of enrolment globally in the TACTI-004 trial speaks to the promise of efti and the need for more efficacious therapies in the first line setting for patients with advanced/metastatic non-small cell lung cancer." The futility analysis and completion of patient enrolment remain on track for the first quarter and third quarter of CY2026, respectively. Announcement here: bit.ly/4ahX2ju #LungCancer #immutep #NSCLC

@Immutep today announces positive update on IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases, from Phase I study. Updates include: - Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levels - Substantial reduction in T cell activity highlights the potential efficacy of IMP761 in treating autoimmune diseases Given encouraging efficacy and safety, the trial will continue as planned and further updates are anticipated in 1H CY2026. Announcement here: bit.ly/3MLogqQ #autoimmune #immutep #autoimmunediseases

@Immutep today reports strong operational progress in the global TACTI-004 Phase III trial evaluating efti in combination with MSD’s anti-PD-1 therapy, KEYTRUDA®, and chemotherapy as first-line therapy for advanced/metastatic non-small cell lung cancer. Updates include: - The TACTI-004 trial has enrolled 289 patients globally, representing over 38% of targeted enrolment - Global progress continues, with more than 120 activated clinical sites and 27 countries having received full regulatory approvals, including the United States Read the full announcement here: bit.ly/44r6rTV #NSCLC #oncology #immunotherapy #immutep

Great to be mentioned in @australian today off the back of announcing our collaboration with Dr. Reddy's on Monday. Scott Power, Senior Research Analyst at Morgans said: "That was a pretty big deal that Immutep announced with Dr.Reddy's and is providing them with important funding from an upfront payment and depending on clinical success there will be more milestone payments come through." "The deal has put Immutep in a solid position and the share price has responded positively." Thanks to Nadine McGrath & Scott Power for the mention. Full article here: bit.ly/4rPLOuu

@Immutep is pleased to announce a new strategic collaboration and exclusive licensing agreement with @drreddys for the development and commercialisation of efti in all countries outside North America, Europe, Japan, and Greater China. Marc Voigt, CEO of Immutep said: “The license agreement with Dr. Reddy’s is a major commercial milestone for Immutep and further validates the significant potential of efti, our first-in-class cancer immunotherapy.” “Dr. Reddy’s is a global pharmaceutical company with proven capabilities in the markets they have licensed for efti. This makes them an ideal partner for us to maximise the commercial benefits from efti outside of North America, Europe, Japan and China. Having recently launched Zytorvi® (toripalimab) as the first and only immunotherapy for nasopharyngeal cancer in Australia, Dr. Reddy’s has a strong track record of bringing cancer therapies to patients.” “In addition to the upfront payment, we stand to earn substantive future milestone and royalty payments. Importantly, we preserve full commercial rights in the world’s largest pharmaceutical markets so we are very well-positioned for future value creation while also maintaining full control of efti’s manufacturing globally, including to Dr. Reddy’s.” Full announcement here: bit.ly/3KNPQmu #Immutep #efti #Oncology #Immunotherapy #Collaboration #DrReddys

Immutep has announced positive data from the EFTISARC-NEO Phase II trial evaluating efti in combination with radiotherapy and pembrolizumab for resectable soft tissue sarcoma (STS). The novel combination achieved a significant 51.5% median tumour hyalinization/fibrosis across multiple STS subtypes, including rare and aggressive tumours with poor prognosis. The promising results warrant further investigation of this novel combination in registrational settings. Click here to see the ASX: bit.ly/4p5Pkid

@Immutep is pleased to share that the EFTISARC-NEO clinical trial evaluating neoadjuvant efti in soft tissue sarcomas has been awarded second place in the distinguished Golden Scalpel Award competition. This competition recognises the most innovative solutions in Polish medicine and is presented by independent experts to initiatives that set new standards in advancing healthcare. This year, EFTISARC-NEO was the only oncology project to receive this accolade, underscoring its leadership and breakthrough potential in cancer treatment. To learn more visit: bit.ly/43W9jaZ Immutep extends its gratitude to the patients and dedicated team at MSCNRIO whose efforts made this achievement possible.

@Immutep is pleased to share positive clinical data presented at the @myESMO Congress 2025. Key highlights: - EFTISARC-NEO Phase II: Met primary endpoint, with the novel combination including efti achieving 51.5% tumour hyalinization/fibrosis in soft tissue sarcoma (p < 0.001). bit.ly/3IVVQsF - INSIGHT-003 trial: Generated strong response rates across all PD-L1 expression levels 1L NSCLC, including 61.7% in low & no PD-L1 (TPS <50%), outperforming historical controls (40.8%). bit.ly/49cf6N4 - A trial-in-progress ePoster for TACTI-004 Phase III trial in 1L NSCLC was also presented. bit.ly/49cf6N4 #ESMO25